TerrAscend Past Earnings Performance
Past criteria checks 0/6
TerrAscend's earnings have been declining at an average annual rate of -20.7%, while the Pharmaceuticals industry saw earnings growing at 26.2% annually. Revenues have been growing at an average rate of 38% per year.
Key information
-20.7%
Earnings growth rate
0.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 38.0% |
| Return on equity | -34.2% |
| Net Margin | -28.7% |
| Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
TerrAscend (TSE:TSND) Takes On Some Risk With Its Use Of Debt
Apr 25
What You Can Learn From TerrAscend Corp.'s (TSE:TSND) P/SAfter Its 25% Share Price Crash
Mar 10Revenues Tell The Story For TerrAscend Corp. (TSE:TSND) As Its Stock Soars 25%
Jan 24Is TerrAscend (TSE:TSND) A Risky Investment?
Dec 25TerrAscend (TSE:TSND) Is Carrying A Fair Bit Of Debt
Aug 13TerrAscend Corp.'s (CSE:TER) Earnings Haven't Escaped The Attention Of Investors
Jul 03TerrAscend (CSE:TER) Is Making Moderate Use Of Debt
Mar 06Is There An Opportunity With TerrAscend Corp.'s (CSE:TER) 37% Undervaluation?
Dec 21Some Analysts Just Cut Their TerrAscend Corp. (CSE:TER) Estimates
Aug 14Is TerrAscend (CSE:TER) Using Too Much Debt?
Jul 15Is TerrAscend (CSE:TER) Using Too Much Debt?
Nov 03Time To Worry? Analysts Just Downgraded Their TerrAscend Corp. (CSE:TER) Outlook
Aug 21Revenue & Expenses BreakdownBeta
How TerrAscend makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 317 | -91 | 115 | 0 |
| 30 Sep 23 | 300 | -50 | 121 | 0 |
| 30 Jun 23 | 277 | -342 | 119 | 0 |
| 31 Mar 23 | 269 | -311 | 122 | 0 |
| 31 Dec 22 | 248 | -304 | 116 | 0 |
| 30 Sep 22 | 212 | -298 | 94 | 0 |
| 30 Jun 22 | 195 | 59 | 88 | 0 |
| 31 Mar 22 | 189 | 13 | 76 | 0 |
| 31 Dec 21 | 194 | 13 | 75 | 0 |
| 30 Sep 21 | 211 | -96 | 88 | 0 |
| 30 Jun 21 | 200 | -165 | 80 | 0 |
| 31 Mar 21 | 175 | -144 | 73 | 0 |
| 31 Dec 20 | 132 | -125 | 61 | 0 |
| 30 Sep 20 | 118 | -159 | 54 | 1 |
| 30 Jun 20 | 99 | -156 | 55 | 1 |
| 31 Mar 20 | 75 | -155 | 49 | 1 |
| 31 Dec 19 | 64 | -161 | 46 | 1 |
| 30 Sep 19 | 48 | -44 | 41 | 0 |
| 30 Jun 19 | 30 | -33 | 32 | 0 |
| 31 Mar 19 | 16 | -23 | 25 | 0 |
| 31 Dec 18 | 5 | -16 | 17 | 0 |
| 30 Sep 18 | 1 | -9 | 12 | 0 |
| 30 Jun 18 | 0 | -8 | 7 | 0 |
| 31 Mar 18 | 0 | -7 | 6 | 0 |
| 31 Dec 17 | 0 | -5 | 5 | 0 |
| 30 Sep 17 | 0 | -5 | 4 | 0 |
| 30 Jun 17 | 0 | -4 | 3 | 0 |
| 31 Mar 17 | 0 | -1 | 1 | 0 |
| 31 Dec 16 | 0 | -1 | 1 | 0 |
| 31 Dec 15 | 0 | -1 | 1 | 0 |
Quality Earnings: TSND is currently unprofitable.
Growing Profit Margin: TSND is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TSND is unprofitable, and losses have increased over the past 5 years at a rate of 20.7% per year.
Accelerating Growth: Unable to compare TSND's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TSND is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (18.4%).
Return on Equity
High ROE: TSND has a negative Return on Equity (-34.18%), as it is currently unprofitable.